XML 29 R16.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Goodwill and Intangible Assets | 3 Months Ended
--- | ---
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and Intangible Assets | 6. Goodwill and Intangible Assets The Company conducts an impairment assessment annually, or more frequently if impairment indicators are present. Changes to the Company’s operating segments effective October 1, 2023 resulted in a change to the Company’s reporting units, which are aligned to the Company’s operating and reportable segments (as further described in Note 15 Segment and Geographic Information). As a result of this segment realignment, the Company allocated goodwill to the reporting units existing under the new organizational structure on a relative fair value basis as of the first quarter of fiscal year 2024. The Company estimated the fair values of the affected businesses based upon the present value of their anticipated future cash flows. The Company’s determination of fair value involved judgment and the use of significant estimates and assumptions, as described in the notes to the audited consolidated financial statements included in the section titled “Financial Statements and Supplementary Data” in Part II, Item 8 of the 2023 Annual Report on Form 10-K and in the “Critical Accounting Policies and Estimates” included in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of the 2023 Annual Report on Form 10-K. In conjunction with the goodwill allocation described above, the Company tested its reporting units for potential impairment immediately before and after the segment realignment and concluded that the estimated fair value of each reporting unit exceeded its respective carrying value. As of October 1, 2023, the fair value of the B Medical Systems reporting unit exceeded its carrying value by approximately 5 percent. In the event the financial performance of any of the reporting units does not meet management’s expectations in the future, the Company experiences a prolonged macroeconomic or market downturn, or there are other negative revisions to key assumptions used in the Discounted Cash Flow (“DCF”) method used to value the reporting units, the Company may be required to perform additional impairment analyses with respect to such reporting unit and could be required to recognize an impairment charge. ​ The following table sets forth the changes in the carrying amount of goodwill by reportable segment since October 1, 2023 (in thousands). The Company has presented the October 1, 2023 balances to be consistent with the current segment structure. ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Sample Management Solutions | ​ | Multiomics | ​ | B Medical Systems | ​ | Total
Balance - October 1, 2023 | ​ | $ | 478,601 | ​ | $ | 196,760 | ​ | $ | 108,978 | ​ | $ | 784,339
Currency translation adjustments | ​ | ​ | 10,925 | ​ | ​ | — | ​ | ​ | 4,902 | ​ | ​ | 15,827
Balance - December 31, 2023 | ​ | $ | 489,526 | ​ | $ | 196,760 | ​ | $ | 113,880 | ​ | $ | 800,166
​ The components of the Company’s identifiable intangible assets as of December 31, 2023 and September 30, 2023 are as follows (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31, 2023 | ​ | September 30, 2023
​ | ​ | ​ | ​ | Accumulated | ​ | Net Book | ​ | ​ | ​ | Accumulated | ​ | Net Book
​ |  | Cost |  | Amortization |  | Value |  | Cost |  | Amortization |  | Value
Patents | ​ | $ | 1,226 | ​ | $ | 1,180 | ​ | $ | 46 | ​ | $ | 1,226 | ​ | $ | 1,175 | ​ | $ | 51
Completed technology | ​ |  | 222,259 | ​ |  | 62,712 | ​ |  | 159,547 | ​ |  | 215,430 | ​ |  | 56,021 | ​ |  | 159,409
Trademarks and trade names | ​ |  | 6,902 | ​ |  | 1,900 | ​ |  | 5,002 | ​ |  | 6,630 | ​ |  | 1,445 | ​ |  | 5,185
Non-competition agreements | ​ | ​ | 681 | ​ | ​ | 588 | ​ | ​ | 93 | ​ | ​ | 681 | ​ | ​ | 568 | ​ | ​ | 113
Customer relationships | ​ |  | 295,879 | ​ |  | 170,338 | ​ |  | 125,541 | ​ |  | 290,800 | ​ |  | 161,257 | ​ |  | 129,543
Other intangibles | ​ | ​ | 907 | ​ | ​ | 907 | ​ | ​ | — | ​ | ​ | 869 | ​ | ​ | 869 | ​ | ​ | —
Total | ​ | $ | 527,854 | ​ | $ | 237,625 | ​ | $ | 290,229 | ​ | $ | 515,636 | ​ | $ | 221,335 | ​ | $ | 294,301
​ Amortization expense for intangible assets was $12.5 million and $11.5 million, respectively, for the three months ended December 31, 2023 and 2022. Estimated future amortization expense for the intangible assets for the remainder of fiscal year 2024 and the subsequent five fiscal years is as follows (in thousands): ​
​ | ​ | ​ | ​
Remainder of fiscal year 2024 | ​ | $ | 38,369
2025 | ​ |  | 49,645
2026 | ​ |  | 46,244
2027 | ​ |  | 37,977
2028 | ​ | ​ | 31,446
2029 | ​ | ​ | 25,590

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//350/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration